- $992.16m
- $495.09m
- $32.33m
US stocks weekly: Unease
Deals of the day-Mergers and acquisitions
Street View: Lilly locks in heart treatment portfolio with Verve buyout
U.S. RESEARCH ROUNDUP- American Airlines, Jabil, Lennar
U.S. STOCKS ON THE MOVE-Natgas companies, Eli Lilly, Kraft Heinz
U.S. STOCKS ON THE MOVE-Red Cat, Nvidia Corp, Redwire
Gene-editing firms rise after Lilly strikes deal to acquire Verve Therapeutics
Verve Therapeutics set for best day ever on Lilly's up to $1.3 billion deal
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Lennar, Jabil, Nvidia
U.S. STOCKS ON THE MOVE-Verve Therapeutics, Lyell Immunopharma, Energy companies
Brief: Lilly To Acquire Verve Therapeutics To Advance One-Time Treatments For People With High Cardiovascular Risk
Verve Therapeutics soars on Eli Lilly's up to $1.3 billion deal
Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say
Verve Therapeutics soars on report Eli Lilly in talks for $1.3 billion deal
Deals of the day-Mergers and acquisitions
Verve Therapeutics jumps on report Eli Lilly eyeing co in up to $1.3 billion deal
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports (updated)
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports